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I was very pleased and honoured when John Collinge
and Michael Alpers invited me to share personal
recollections about research on kuru and related
diseases during the more than 25 years I spent at the
National Institutes of Health (NIH). Such reminis-
cences must be impossibly arbitrary and awkwardly
abbreviated when condensed to such a short contri-
bution, so I hope that readers of this paper and others
among the many people involved in the work who
survive will forgive my inevitable omissions, failures to
remember or to credit worthy contributors, and
misunderstandings regarding who ﬁrst conceived of
or initiated various aspects of the research. I shall
recount my own history at the NIH and summarize a
few selected important scientiﬁc achievements for
which, I believe, NIH research investigators—taken
broadly to include some collaborating investigators—
were largely responsible, and I shall add a few
personal reminiscences.
In July 1966, I arrived at the laboratory of Daniel
Carleton Gajdusek in what was then the National
Institute of Neurological Diseases and Blindness
(NINDB), one of the NIH in Bethesda, Maryland. I
came because I was introduced to Carleton’s work with
kuru by David Lang, infectious disease physician and
my mentor during my last year of residency training in
paediatrics at the Massachusetts General Hospital
in Boston. I came as a Public Health Service (PHS)
ofﬁcer—the Vietnam War having intensiﬁed young
physicians’ interest in PHS-sponsored research—and
was later sent, supported by an NIH Special Fellowship
sponsored by Carleton, to what was then the Soviet
Union. I returned to his laboratory as a civilian research
medical ofﬁcer late in the summer of 1970 and
remained with the NIH programme, participating in
studies of kuru and related diseases (transmissible
spongiformencephalopathies(TSEs)orpriondiseases)
and other infectious diseases for the next 25 years. At
the end of August 1995, I left the NIH to head a small
laboratory at the US Food and Drug Administration
(FDA) Center for Biologics Evaluation and Research,
where I still work today.
By the time I joined Carleton Gajdusek’s research
group at the NIH, kuru had already been recognized as
a novel degenerative brain disease caused by a ‘slow’
scrapie-like infection transmitted to chimpanzees, and
kuru’s similarities to Creutzfeldt–Jakob disease (CJD)
noted. Other animals and cell cultures were already on
test as possible assays for infectivity, and collections of
tissue samples from cases of CJD had begun. The
group’s working hypothesis was that the aetiological
agent was probably an unconventional virus. Clarence
Joseph Gibbs Jr (Joe Gibbs)—working in borrowed
space at the US Department of Interior’s Patuxent
Wildlife Research Center, where the laboratory’s
primates and other animals were housed—agreed to
train me in medical virology and applied primatology;
our very close association lasted until Joe’s death. I had
the bittersweet honour of delivering Joe’s ﬁnal planned
public presentation, an invited talk on the pathogenesis
of human TSEs before the FDA TSE Advisory
Committee, weeks before he died in February 2001.
In July 1966, when I arrived at the NIH, Michael
Alpers was a Visiting Scientist at NIH and he, Carleton
and Joe had just published a monograph on Slow, latent
and temperate virus infections (Gajdusek et al. 1965) that
was for many years a deﬁnitive source of information
on kuru and scrapie and that remains an important
historical document. In short, I was neither ‘present
at the creation’ of Carleton’s NIH laboratory nor did
I stay until its end.
Carleton’s laboratory at the NIH can be considered
to have begun 8 years before I arrived. In 1958 he was
appointed Visiting Scientist of NINDB, although, as
recordedincorrespondence regarding kuruwith Joseph
E. Smadel (ﬁgure 1; Farquhar & Gajdusek 1981), NIH
had already provided logistical support for ﬁeldwork
from the summer of the previous year. Carleton had
learned of kuru while a Fellow of the National
Foundation for Infantile Paralysis in the Melbourne
laboratory of Sir Macfarlane Burnet, who appears to
have been considerably less enthusiastic about support-
ing Carleton’s involvement in kuru research than was
Smadel. In 1956, Smadel had left the Walter Reed
Army Institute of Research, Washington, DC, where he
had worked with Carleton from 1952, to become
Associate Director of NIH. At the NIH, Smadel was
the earliest strong proponent of Carleton’s ambitious
research plans and occupied a position where he could
help realize them; Smadel was clearly responsible for
recognizing Carleton’s promise, inviting him to the
NIH, fostering his early career there, and introducing
and recommending him to suitable collaborators at
the NIH. Many subsequent NIH administrators were
also very supportive, at least until 1994.
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research in the NIH laboratory shifted from kuru to
otherdiseases—probablyduetoasteadydeclineinkuru
cases after the 1960s and the growing number of other
TSE cases referred to the group. But kuru remained the
ﬁrst disease among equals when competing for Carle-
ton’s attention. There was no time after which kuru
research stopped, and I cannot discriminate mean-
ingfully between those NIH colleagues who worked
directly with kuru and those who did not—Carleton
tried to engage us all in one aspect of kuru or another.
The NIH laboratory remained under Carleton’s
direction for approximately 38 years; in January 1995,
he announced to NIH administrators his intention to
end the research programme (prompting me to take
another job later that year), and he left NIH the next
year. Staff remaining in the laboratory continued to
conduct TSE research for 8 more years, as Joe Gibbs
attempted to bring Carleton’s programme to an orderly
conclusion. With the retirement, in July 2004, of Paul
Brown, the last investigator actively engaged in TSE
research on the NIH Bethesda campus, Carleton’s
laboratory ceased to exist, although the NIH continues
to maintain some laboratory records and a collection of
research samples. During his last years at NIH, Paul
Brownbecame the veryeffective chairman of the FDA’s
TSE Advisory Committee, and he remains a sought-
after consultant.
1. KURU AND CREUTZFELDT-JAKOB DISEASE
(a) Recognition that kuru was a novel
neurodegenerative disease
I am particularly glad to have known Vincent Zigas
(see ﬁg. 2 in Gajdusek 2008), who was the ﬁrst trained
physician to recognize kuru as a fatal neurological
disease not previously described and to consider the
possibility that it might be an infection. But, although
Vin might have somewhat resented a relative lack of
recognition for those insights, he remained extremely
close to Carleton, who appreciated and publicly
acknowledged Vin’s contribution to the understanding
of kuru. Vin, in turn, was grateful to Carleton for
overcoming administrative obstacles that had impeded
the study of kuru and for planning, organizing and
leading as well as tirelessly participating in the research
studies at Okapa that led to the seminal descriptions of
kuru in the medical literature at the end of 1957
(Gajdusek & Zigas 1957; Zigas & Gajdusek 1957).
Vin—who, I believe, spoke four other languages better
than his famously mangled English—had a wonderful
singing voice and a comic ﬂair; he was a special
favourite of our older son, whom he entertained in the
mid-1970s with rousing slapstick renditions of the
Russian popular song Kapitan.
(b) Hypothesis and conﬁrmation that kuru
was an infectious disease experimentally
transmissible to animals
The hypothesis that kuru, like scrapie, might be
transmissible to animals closely related to the natural
host but causing overt disease only after exceptionally
long incubation periods is generally credited to William
Hadlow (1959), who, like Carleton Gajdusek, also
went on to study TSEs at the NIH, but more than a
thousand miles from Bethesda. At least through last
year, Bill Hadlow was still consulting on the pathology
of animal TSEs. It is puzzling to me that Bill—having
offered the insight that eventually led to solving the
mystery of the kuru outbreak—never involved himself
in research on kuru orCJD. On the other hand, it seems
ironic that the scrapie research unit Bill started at the
Rocky Mountain Laboratory of the National Institute
of Allergy and Infectious Diseases, in Hamilton,
Montana, developed into the only TSE research
laboratory remaining in the NIH Intramural Research
Program today.
The demonstration by Carleton Gajdusek, with
Michael Alpers, Joe Gibbs and colleagues, that kuru
was experimentally transmissible to chimpanzees
(ﬁgures 2 and 3; Gajdusek et al. 1966), and later to
monkeys (ﬁgure 4; Gajdusek et al. 1968), remains, at
least in my opinion, the single most important event in
uncovering the aetiology and epidemiology of human
TSEs. Only someone with both the appetite for high-
risk research and unusual persuasive powers of
Carleton Gajdusek could have convinced generally
conservative NIH administrators to fund (and maintain
during several years of negative results) the expensive
and exotic programme needed to conﬁrm the kuru–
scrapie hypothesis. After 42 years of experience work-
ing for the US government, I still cannot imagine how
Figure 1. Joseph E. Smadel, sometime in the 1950s (from the
archives of Clarence J. Gibbs, Jr and the Laboratory of
Central Nervous System Studies, NIH).
Figure 2. A chimpanzee with early signs of experimental kuru
(drooping lower lip) at the Patuxent Wildlife Research
Center, 1967 (from the Gibbs archives).
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enthusiastic and powerful champion like Smadel, who
died in 1963. Once the programme had begun, the
dedicated support of other colleagues, both in
the laboratories and in the administrative ofﬁces of
the NIH, was essential to its later success.
(c) Hypothesis and conﬁrmation that sporadic
Creutzfeldt–Jakob disease (sCJD) was similar
in aetiology to kuru
Even before the published descriptions of kuru and
Hadlow’s observation, and 6 years before the successful
transmission of kuru to primates, an NIH investigator
took a critical step in understanding the human TSEs.
Immediately after examining the histopathology of the
ﬁrst of six brains from people dying with kuru sent to
the NIH, Igor Klatzo, chief of neuropathology in
NINDB, remarked in a letter to Carleton in Okapa
(Farquhar & Gajdusek 1981) that, ‘It [kuru] seems to
be deﬁnitely a new condition without anything similar
described in the literature. The closest condition that I
can think of is that described by Jacob [sic] and
Creutzfeldt.’ After 2 years, with Gajdusek and Zigas,
Klatzo published his observations on the histopatholo-
gical similarities between kuru and CJD (Klatzo et al.
1959) or, as Nevin and others in the UK called it,
subacute spongiform encephalopathy (Nevin et al.
1960) — t h en a m et h a tJ o eG i b b sa n dC a r l e t o n
Gajdusek later proposed for the entire class of
scrapie-like diseases (Gibbs et al. 1968; Gibbs &
Gajdusek 1969). Just as I cannot understand why Bill
Hadlow never studied kuru, I have wondered why Igor
Klatzo, following his ﬁrst seminal contribution, pre-
pared several more important publications on kuru but
then turned his attention to in vivo studies of the blood
brain barrier in sharks (ﬁgure 5) and other models but
never returned to the TSEs. Igor spent many years
retired not far from Bethesda, and he maintained an
indirect connection with TSEs through his friendship
with Jurai Cervenak and Larisa Cervenakova, both of
whom are colleagues still working with TSEs, Jurai at
the FDA and Larisa at the American Red Cross.
IgorKlatzo’sobservationledElisabethBeck(ﬁgure6),
whostudiedscrapie(Becketal.1964)inherlaboratoryat
the Maudsley Institute in London and later compared
the neuropathology of kuru in humans with the
experimental disease in chimpanzees and monkeys
(Beck et al. 1966, 1969), to obtain and send the ﬁrst
samplesofbraintissuesfrompatientswithCJD(ﬁgure7)
tothe NIH laboratory.CJD wassuccessfully transmitted
from those samples, and later many others, to
Figure 4. MacFarlane Burnet (left), Joe Gibbs and a spider
monkey with experimental kuru, ca 1971 (from the Gibbs
archives).
Figure 5. Igor Klatzo in diving gear, preparing to study
sharks, in the late 1960s (from the Gibbs archives).
Figure 3. The author and friends at the Patuxent Wildlife
Research Center, ca 1968 (from the Gibbs archives).
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rodents, demonstrating that TSEs affected people
throughout the world, not just in Papua New Guinea,
and that the spectrum of scrapie-like infections in
humans must be greater than ﬁrst suspected. Until late
in her life, Elisabeth continued to study the histopathol-
ogy and eventually the ultrastructural pathology of
human TSEs (Beck et al. 1975), as she had studied
scrapie earlier. Elisabeth doted on Carleton and Joe, but
not enough to overcome her intolerance of jet lag and
especially her great distaste for the hot and humid
weather that plagues Washington from late spring
through early autumn; during her last summer visit, she
announced that if we ever wanted to see her again it had
to be in London or at her home in Epsom, but not in
Washington. Her aversion to travel apparently extended
only westward; she loved walking in the mountains near
Arosa, Switzerland each summer. After retiring from the
Maudsley,ElisabethenjoyedayearworkinginGermany,
only one time zone away from Epsom, gratefully
accepting an honorary medical degree and trying to
forget the humiliation of her exile during World War II.
It was unquestionably the demonstration by the
NIH group that CJD was a second human TSE, so
that kuru did not just represent a one-off exotic
disappearing disease resulting from cannibalism—and
that there existed a whole class of previously unsus-
pected infectious agents capable of transmitting non-
inﬂammatory progressive neurological diseases years
after exposure—that was the discovery that resulted in
the Nobel Prize in Physiology or Medicine being
awarded to Carleton in 1976 (Gajdusek 1977).
(d) Demonstration that familial CJD and
Gerstmann–Stra ¨ussler–Scheinker syndrome
were associated with aetiological agents similar
to that causing sporadic CJD
Walter R. Kirschbaum, like Elisabeth Beck, a product of
the classical German school of neurology and fortunate
to have left Germany before the War (in his case
emigrating to Chicago), ﬁrst described CJD in members
of the famous Backer family (Kirschbaum 1924)—a
huge German kindred with familial CJD expressed in an
autosomal dominant pattern (Meggendorfer 1930).
Kirschbaum, author of a prodigious summary of the
ﬁrst 150 published cases of ‘Jakob–Creutzfeldt disease’
(Kirschbaum 1968), preferred the names in reverse
chronological order (perhaps doubting that Creutz-
feldt’s case was really the same disease). He was
sufﬁciently impressed by the model of kuru to comment
presciently that ‘The slow-virus concept applicable to
other neurologicaldiseasesshouldnotbedismissedfrom
pathogenetic considerations of J–C disease.’ Prof.
Kirschbaum visited the NIH laboratories in the early
1970s. He was clearly a ﬁne neurologist but exception-
ally sensitive to imagined slights; I recall his waiting in a
line for taxis to a dinner and rebuking me that ‘This lady
Figure 6. Elisabeth Beck at the Oxford home of H. B.
(James) Parry, proponent of the genetic theory for scrapie,
1970 (from the author’s collection).
Figure 7. Cortical biopsy of the ﬁrst patient with CJD sent
to the NIH by Elisabeth Beck in 1966 (from Elisabeth
Beck’s collection).
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patiently that the lady was my wife.
It was Colin Masters during his years at the NIH
who ﬁrst noted that some cases of CJD that had
transmitted disease to animals were familial (Masters
et al. 1979) and that some of the familial transmitted
cases were better diagnosed as examples of the
Gerstmann–Stra ¨ussler–Scheinker (GSS) syndrome
(Masters et al. 1981). I am still not sure that the
somewhat arbitrary distinction between familial CJD
and GSS is important for understanding the aetiology
of TSE infections and effects of host genetics, but that
is a small point. I consider the demonstration that
familial as well as sporadic human TSEs are associated
with, if not caused by, infectious agents similar to
those responsible for sporadic CJD to be a major
accomplishment of the NIH TSE programme that
began with kuru.
(e) Use of animal assays to elucidate the tissue
distribution of the infectious agent in kuru
and TSEs
The elaborate efforts of Carleton Gajdusek, Joe Gibbs
and colleagues to address the hypothesis that other
chronic progressive neurological diseases might be
caused by agents similar to those transmitting kuru and
CJD/GSS uncovered no unsuspected TSEs among the
more common ailments, such as Alzheimer’s disease or
multiple sclerosis. However, the studies—sometimes
ridiculed then as ‘Noah’s ark’ transmission attempts—
resulted in another contribution: they helped to reveal
the distribution of infectivity in various tissues of
people dying with kuru or CJD, information that
remains important today (Brown et al. 1994). The
NIH studies were the ﬁrst to demonstrate that
infectivity in the blood of an animal model was highly
associated with nucleated cells (Kuroda et al. 1983),
and two alumni of the NIH group, Paul Brown and
Robert Rohwer, and colleagues, later extended that
work to show that plasma, but probably not erythro-
cytes or platelets, also contained a large fraction of
the total infectivity in blood (Brown et al. 1998;
Gregori et al. 2004). Bob Rohwer, now Professor at the
University of Maryland/Baltimore Veterans Adminis-
tration Health Center and head of the Baltimore
Research and Education Foundation, has since
gone on to develop an interesting candidate device
for removing infectivity from blood (Gregori
et al. 2006a,b).
2. RECOGNITION OF IATROGENIC
TRANSMISSION OF CJD
Another contribution resulted from a collaborative
effort between Christoph Bernoulli, then at the Zurich
Kantonsspital, and the NIH kuru research group. Chris
recognized that a cortical electrode probe had trans-
mitted CJD from an older patient to two young people
undergoing epilepsy surgery (Bernoulli et al. 1977).
An earlier clinical report described a transmission
by a transplanted cornea (Duffy et al. 1974), but iatro-
genic CJD from contaminated instruments—though
suggested indirectly by Nevin’s case series (Nevin et al.
1960)—had not been reported. Chris enlisted the
assistance of our group at the NIH, both to prepare his
report for publication and to assay the actual impli-
cated probe for residual infectivity. The dramatic
transmission of CJD by implanting pieces of the
probe in the frontal lobe of a chimpanzee (Gibbs
et al. 1994) eliminated any doubt that conventional
cleaning and sterilization had failed to remove residual
infectivity. Similar studies assaying retention lots of
human cadaveric pituitary growth hormone (Gibbs
et al. 1993) served a similar purpose in conﬁrming
experimentally the clinical evidence of iatrogenic
transmissions of CJD by that product. I hope that
Chris Bernoulli ﬁnally made his peace with what
happened in Zurich so many years ago and takes
comfort in having played a critical role in promoting
awareness of the potential risk from contamination
of neurosurgical instruments with TSE agents. It is
probably not coincidental that, in spite of increased
surveillance, no case of iatrogenic CJD has been
attributed to contaminated surgical instruments for
many years (Foncin et al. 1980).
3. DEMONSTRATION OF THE UNUSUAL
PHYSICAL PROPERTIES OF THE TSE AGENTS
The NIH kuru research programme also contributed
to the improved understanding of the unique physical
properties of the TSE agents. The hypothesis that
scrapie was caused by a unique pathogen with physical
properties so unusual as to be inconsistent with a
nucleic acid encoding the synthesis of its components
and its self-replication was already circulating when
I arrived in Carleton’s group in 1966. Pattison and
Sansom had concluded, in 1964, that the scrapie agent
was dialysable through pores too small to admit the
passage of viruses (Pattison & Sansom 1964; Pattison
1965; Pattison & Jones 1967) and Alper and colleagues
had just reported the results of her ﬁrst studies with
ultraviolet light inactivation that they interpreted as
inconsistent with a nucleic acid component of the
agent (Alper et al. 1966). Grifﬁth offered a number
of possible mechanisms by which a nucleic-acid-
free agent might encode pathogenic self-replicating
information (Grifﬁth 1967). NIH investigators were
involved in conﬁrming and extending those obser-
vations to other TSE agents and ionizing radiation
(Latarjet et al. 1970; Latarjet 1979), while warning that
estimates of maximal size of nucleic acid in TSE agents
based on inactivation by irradiation were probably too
small (Rohwer & Gajdusek 1980; Rohwer 1984a,
1986). Bob Rohwer’s studies at the NIH suggested
that most infectivity of the scrapie agent was, contrary
to previous reports, destroyed by boiling (Rohwer
1984b) and that its resistance to heat inactivation
resulted from a very small resistant fraction; my own
modest contribution was to show that drying on to
surfaces seemed to protect infectivity from inactiva-
tion (Asher et al. 1986b, 1987), a ﬁnding of practical
importance (Grobben et al. 2005) that I under-
estimated at the time. The discovery of the prion
protein, the elucidation of its role in susceptibility to
TSE infection and the genetic basis of familial TSEs,
followed by the full elaboration of what came to be
known as the ‘prion’ or ‘all-protein’ hypothesis for the
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from the Nobel prize-winning work of Stanley
Prusiner and colleagues (Bolton et al. 1982; Prusiner
1982, 1997), although we later recognized the use of
the newly described abnormal prion protein for the
improved diagnosis of TSEs (Brown et al. 1986). NIH
staff were also involved in the earliest descriptions of
unusual tubulovesicular particles commonly associated
with TSEs (David-Ferreira et al. 1968) that sceptics
of the prion hypothesis still propose as possible
nucleic-acid-containing aetiological agents of TSEs
(Manuelidis et al. 2007). Until the very end of the
NIH laboratory, we never reached consensus in our
views about the all-protein hypothesis for the probable
nature of TSE agents.
4. COLLABORATIVE NATURE OF RESEARCH ON
KURU AND OTHER TSEs AT THE NIH
During those years, in addition to resident staff and
many predoctoral and postdoctoral fellows, a series of
visiting scientists joined the kuru research programme
for periods of months or years. I can remember and
name at least 100 of the colleagues whom I worked with
or who were part of Carleton’s team in the laboratory
during my time at the NIH. A dozen or more of them
have died, some have retired but most are still
professionally active and several are internationally
prominent scientists. Of the many support and
technical staff involved in kuru research at the NIH, I
particularly remember Mint Basnight, Alfred Bacote,
Don Cameron Jr, Olive Childers, Laura Kreiss, Steven
Ono, Kitty Pomeroy, Linda Poole, Ginny Rousculp,
John and Dory Runman, Gary Stone, Michael Sulima
and LaDonna Tavel; Ivan Mbaginta’o, Marion Poms
(who was Carleton’s devoted secretary from his arrival
at the NIH in 1958), Nancy Rogers and Lucille Gilbert
have died. Then there are the enormous number of
collaborating scientists within the NIH and elsewhere
who did not work in the kuru laboratory but
contributed in other important ways, supporting
Carleton and Joe and maintaining the intellectual
ferment that enabled success. It would be a daunting
task to try and acknowledge everyone who contributed
to this remarkable enterprise.
5. CONTINUING INFLUENCE OF THE NIH KURU
RESEARCH IN MY OWN LIFE
Since 1996, Pedro Piccardo, Kitty Pomeroy (both NIH
alumni), others at the FDA and I, with Larisa
Cervenakova, also an alumna of the NIH TSE
programme and now directing her own laboratory at
the American Red Cross, have continued to study those
same diseases and some of the same issues that were the
object of my earliest efforts when I came to work with
Joe Gibbs, Michael Alpers and Carleton Gajdusek at
the NIH 42 years ago. Our group at the FDA has been
evaluating the resistance of cell cultures (Asher et al.
1979; Yanagihara et al. 1980), in particular cells used as
‘substrates’ for generating vaccines and other biological
products, to infection with the agent of bovine spongi-
form encephalopathy and other TSE agents. I am also
slowly completing applied work begun 28 years ago on
methods for decontaminating TSE agents dried onto
surfaces (Asher et al. 1986a,b, 1987). I hope that my
younger colleagues will soon expand our studies in the
FDA to evaluate candidate ante-mortem diagnostic
tests for TSEs and practical devices for removing the
infectious agents from blood and other ﬂuids used in
the manufacture of biologicals. We also serve FDA as
sources of historical and technical information about
TSE infections (Buckner & Asher 2008) and their
implications for regulatory actions and public health
policies affecting the safety of blood components,
plasma derivatives, vaccines, medical devices and
other medical products (Asher 1999a,b). So it is clear
that early experience with kuru research at the NIH
inﬂuenced the rest of my professional life. It indirectly
beneﬁted my personal life as well, but that story I leave
for another time and place.
T h eo p i n i o n si nt h i sa r t i c l eh a v en o tb e e nf o r m a l l y
disseminated by the United States Food and Drug Admin-
istration and should not be construed to represent any
Agency determination or policy.
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